Kezar Life Sciences, Inc.

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Clinical Advisory Committee
  • Pipeline
    • Overview
    • KZR-616
    • KZR-261
  • Our Science
    • Overview
    • Medical & Scientific Presentations
    • Publications
  • Clinical Trials
  • Investors & News
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Medical & Scientific Presentations

Our Science

Our Science

  • Overview
  • Medical & Scientific Presentations
  • Publications
Nov 8, 2019

Targeting Multiple Immune Checkpoint Proteins With Novel Small Molecular Inhibitors of Sec61-dependent Cotranslational Translocation

Kezar Life Sciences, Inc

Nov 5, 2019

The Pharmacokinetic Differences Between Humans and Animals of KZR-616, a First-In-Class, Selective Immunoproteasome Inhibitor, In Two Clinical Formulations

Kezar Life Sciences, Inc

Jun 13, 2019

Treatment of Systemic Lupus Erythematosus Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 2 Cohorts of an Open-label Phase 1b Dose Escalation Trial

Kezar Life Sciences, Inc

Apr 10, 2019

Proteomic Profiling of a Novel Anti-Cancer Small Molecule Inhibitor of Sec61

Kezar Life Sciences, Inc.

Apr 6, 2019

KZR-616, A Selective Inhibitor of the Immunoproteasome, Attenuates the Development of Murine Lupus Nephritis

Kezar Life Sciences, Inc.

Apr 2, 2019

KZR-8834: A Novel, Small Molecule Inhibitor of Sec61-Dependent Protein Secretion with Anti-Tumor Activity

Kezar Life Sciences, Inc.

Apr 2, 2019

Discovery and Characterization of Novel Anti-Cancer Small Molecule Inhibitors of Sec61

Kezar Life Sciences, Inc.

Nov 6, 2018

Pharmacokinetics, Pharmacodynamics, and Their Relationship of KZR-616 in Healthy Volunteers

Kezar Life Sciences, Inc.

Nov 5, 2018

Role of Epoxide Hydrolases and Cytochrome P450s on Metabolism of KZR-616, a First-in-Class Selective Inhibitor of the Immunoproteasome

Kezar Life Sciences, Inc.

Nov 4, 2017

Selective Inhibition of the Immunoproteasome Subunit LMP7 is Not Sufficient for Blocking Cytokine Production or Attenuating Progression of Experimental Arthritis

Kezar Life Sciences, Inc.

RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • Next »
Kezar Life Sciences, Inc.
  • About Us
  • Pipeline
  • Our Science
  • Clinical Trials
  • Investors & News
  • Careers
Contact Us

4000 Shoreline Court , Suite 300
South San Francisco, CA 94080

Linkedin Facebook Twitter YouTube

© 2022 Kezar Life Sciences, Inc. All Rights Reserved.

Privacy Policy Disclaimer Sitemap